Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis

Rheumatology International

Volumn 26, Issue 5, 2006, Pages 445-453

  Nuti, R ^a   Bianchi, G ^b   Brandi, M L ^c   Caudarella, R ^d   D'Erasmo, E ^e   Fiore, C ^f   Isaia, G C ^g   Luisetto, G ^h   Muratore, M ⁱ   Oriente, P ⁱ   Ortolani, S ⁱ  

^a UNIVERSITY OF SIENA   (Italy)

^b Ospedale La Colletta   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALPHAD3; ASCORBIC ACID; CACIT D3; CALCIUM CARBONATE; DISEON;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM CARBONATE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 33644619587     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-005-0073-4     Document Type: Article

References (45)

1. 3 in the pathogenesis and treatment of osteoporosis. Osteoporos Int 7(Suppl 3):S24-S29
2. 3. J Bone Miner Metabol 10(2):184-188
3. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. New Engl J Med 326(6):357-362
4. 3) and calcium in osteoporosis. Clin Orthop 300:241-247
5. 3 on lumbar bone mineral density, vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370-376
6. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43(2):211-220
7. Nuti R, Martini G, Valenti R, Giovanni S (1996) Controlled study on the metabolic and absorptiometric effects of calcitriol in involutional osteoporosis. Clin Drug Invest 11(5):270-277
8. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618-3628
9. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G (2002) The osteoporosis methodology group, and the osteoporosis research advisory group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560-569
10. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320-323
11. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113(9):649-655
12. 2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 6:284-290
13. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63-70
14. Scharla SH, Schacht E, Bawey S, Kamilli I, Holle D, Lempert UG (2003) Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthritis Rheuma 23(5):268-274
15. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642
16. 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13:257-264
17. Cooper L, Clifton-Bligh PB, Nery ML et al. (2003) Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr 77:1324-1329
18. 3 in Japan. Akt Rheumatol 19(Suppl 1):27-30
19. 3 analogues for the treatment of Osteoporosis. Osteoporosis Int 3(Suppl 1):S190-S193
20. Schacht E (1999) Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 65:317-327
21. Grassi F, Leavey JK, Dark K, Qian W, Weitzmann MN, Pacifici R (2004) Bone marrow restricted antigen presentation by dendritic cells induces T cell activation and T CELL TNF production in ovariectomized mice. J Bone Miner Res 19(Suppl 1):S16
22. Horst RL, Goff JP, Reinhardt TA (1990) Advancing age results in reduction of intestinal and bone 1,25-dihydroxy-vitamin D receptors. Endocrinology 126(2):1053-1057
23. Rapuri PB, Gallagher JC, Haynatzka V (2004) Interaction between vitamin D receptor and estrogen receptor genotypes does not influence BMD, rate of bone loss and the response to treatment with calcitriol or estrogen in elderly women. J Bone Miner Res 19(Suppl 1):S246
24. Nordin BEC, Need AG, Morris HA, Horowitz M (1999) The special role of "Hormonal" forms of Vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:307-310
25. Lau KHW, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295-306
26. Ringe JD, Schacht E (2004) Prevention and therapy of osteoporosis: the respective roles of plain vitamin D and alfacalcidol. Rheumatol Int 24:189-197
27. 3 receptors by blocking Ubiquitin/Proteasome-mediated degradation in human skin. Mol Endocrinol 13(10):1686-1694
28. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622-629
29. van Driel M, Pols HAP, van Leeuwen JPTM (2004) Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 10:2535-2555
30. DeLuca HF, Cantorna MT (2001) Vitamin D. Its role and uses in immunology. FASEB J 15:2579-2585
31. 3 analogs as immunomodulatory agents. Trends Mol Med 8:174-179
32. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct action from estrogen. J Bone Mineral Res 15:770-779
33. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E (1999) The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311-316
34. 3 on bone loss by ovariectomy in aged rats. Jpn. J. Pharmacol 89:255-266
35. Duque G, El Abdaimi K, Henderson JE, Lomri A, Kremer R (2004) Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 35:57-64
36. 3 are detected only in the presence of a powerful antiresorptive. J Bone Min Res 19(Suppl 1):S483
37. 3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U.S.A. 98(12):6800-6805
38. 3 on loss of bone mineral density immediately after artificial menopause. Endocr J 44(2):299-304
39. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) The osteoporosis methodology group, and the osteoporosis research advisory group. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
40. Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301-310
41. Richy F, Schacht E, Bruyère O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76(3):176-186
42. Bock O, Boerst H, Degner C, Stephan-Oelkers M, Felsenberg D (2004) Underestimated musculoskeletal adverse effects of oral treatment with once weekly alendronate 70 mg and risedronate 35 mg: including possibilities for their prevention. Osteoporos Int 15(Suppl 1):S106
43. Compston JE (2004) The risks and benefits of HRT. J Musculoskel Neuron Interact 4(2):187-190
44. Ushiroyama T, Ikeda A, Sakai M, Higashiyama T, Ueki M (2003) Prevention of postmenopausal bone loss with exchange for short-term HRT for 1α-hydroxycholecalciferol. Maturitas 45:119-127
45. Shiraishi A, Ito M, Hayakawa N, Kubota N, Imai N (2004) Combination therapy with alfacalcidol and risedronate at their subtherapeutic doses can additively improve bone dynamics in ovariectomized rat model of osteoporosis. J Bone Miner Res 19(Suppl 1):S180